TRPC1 and Huntington disease: EVP4593 attenuates enhanced SOCE. EVP4593 affects heteromeric channels containing the TRPC1 subunit but has no effect on homooligomer channels composed of TRPC1. EVP4593 delays a progression of a motor dysfunction phenotype in a transgenic fly HD model and protects YAC128 MSNs in a glutamate toxicity assay.